Key result
Scoping review protocol outlines evaluation of GLP-1 receptor agonists for major cardiovascular events prevention in type 2 diabetes.
Why the study?
The available scientific evidence on the impact of GLP-1 RAs on the prevention of MACE in adults with T2DM needs to be mapped and synthesized to identify knowledge gaps and support clinical decision-making.
Does glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy prevent major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus (T2DM)?
Does glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy prevent major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus (T2DM)?
Answers are grounded in this paper and cite their sources.
This scoping review protocol outlines a plan to map and synthesize scientific evidence on the impact of GLP-1 receptor agonists on preventing major adverse cardiovascular events in adults with type 2 diabetes mellitus.
This scoping review will aim to map and synthesize the available scientific evidence on the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on the prevention of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus (T2DM). The review will be conducted in accordance with the methodological recommendations of the Joanna Briggs Institute (JBI) and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). The research question will be formulated using the Population, Concept, and Context (PCC) framework. Searches will be performed in MEDLINE/PubMed, the Virtual Health Library (VHL), and the Cochrane Library. Eligible publications will include primary studies, systematic reviews, clinical practice guidelines, and consensus documents addressing cardiovascular outcomes associated with GLP-1 RA therapy. Two independent reviewers will screen titles, abstracts, and full texts according to predefined eligibility criteria, with disagreements resolved through consensus or consultation with a third reviewer. Data will be extracted using a standardized instrument and synthesized descriptively to characterize the therapeutic interventions, cardiovascular outcomes, clinical applicability, and existing knowledge gaps. The review is expected to provide a comprehensive overview of the evidence regarding the cardiovascular benefits of GLP-1 RAs, supporting evidence-based clinical decision-making and identifying priorities for future research.
No takes yet. Share an insight, caveat, or question.
Lucas Dalvi Armond Rezende (2026) conducted a review in Type 2 diabetes mellitus. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was evaluated on Prevention of major adverse cardiovascular events (MACE). Glucagon-like peptide-1 receptor agonists will be evaluated in this scoping review protocol for the prevention of major adverse cardiovascular events in adults with type 2 diabetes; no results yet.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: